scholarly journals Short-Term Therapy with Luliconazole, a Novel Topical Antifungal Imidazole, in Guinea Pig Models of Tinea Corporis and Tinea Pedis

2012 ◽  
Vol 56 (6) ◽  
pp. 3138-3143 ◽  
Author(s):  
Hiroyasu Koga ◽  
Yasuko Nanjoh ◽  
Hideo Kaneda ◽  
Hideyo Yamaguchi ◽  
Ryoji Tsuboi
Keyword(s):  
Tinea Pedis ◽  
Day Treatment ◽  
Skin Lesions ◽  
Term Treatment ◽  
Tinea Corporis ◽  
Term Therapy ◽  
Short Term ◽  
Short Term Treatment ◽  
Treatment Regimens ◽  
Short Term Therapy

ABSTRACTLuliconazole is a novel topical antifungal imidazole with broad-spectrum and potent antifungal activity. The drug is under clinical development in the United States for management of dermatophytosis with a short-term treatment regimen. The present study was undertaken to investigate the clinical benefit of short-term therapy with luliconazole cream in guinea pig models of tinea corporis and tinea pedis induced withTrichophyton mentagrophytes. The dose-dependent therapeutic efficacy of topical luliconazole cream (0.02 to 1%), measured by macroscopic improvement of skin lesions and by fungal eradication as determined by a culture assay, was demonstrated using a tinea corporis model. The improvement in skin lesions seen with luliconazole cream was observed even at a concentration of 0.02%, and its efficacy at 0.1% was equal to that of 1% bifonazole cream. The efficacy of short-term therapy with 1% luliconazole cream, which is used for clinical management, was investigated using the tinea corporis model (4- and 8-day treatment regimens) and the tinea pedis model (7- and 14-day treatment regimens). The 1% luliconazole cream completely eradicated the fungus in half or less of the treatment time required for 1% terbinafine cream and 1% bifonazole cream, as determined by a culture assay for both models. These results clearly indicate that 1% luliconazole cream is sufficiently potent for short-term treatment for dermatophytosis compared to existing drugs. Luliconazole is expected to be useful in the clinical management of dermatophytosis.

scholarly journals Short versus long course antibiotic therapy for acute pyelonephritis in adults: a systematic review and meta-analysis

2018 ◽  
Vol 12 (1) ◽  
pp. 39
Author(s):  
Franco Berti ◽  
Tiziana Marcella Attardo ◽  
Salva Piras ◽  
Letizia Tesei ◽  
Daniela Tirotta ◽  
...  
Keyword(s):  
Acute Pyelonephritis ◽  
Term Treatment ◽  
Term Therapy ◽  
Short Term ◽  
Short Term Treatment ◽  
End Of Treatment ◽  
Long Term Treatment ◽  
Short Term Therapy ◽  
Long Course ◽  
Quality Evidence

Acute pyelonephritis (aPN) is defined as a severe form of urinary tract infection. Despite its severity and the high incidence in the community setting, there is no consensus on the optimal duration of treatment. The aim was to compare effectiveness and tolerability of short- versus long-course treatment with the same antibiotic agent in patients with aPN. We searched MEDLINE (PubMed), EMBASE and CENTRAL up to June 2016 for randomized controlled trials (RCTs). Three pairs of authors independently extracted data and appraised risk of bias. We included 4 RCTs (439 participants). Short antibiotic treatment lasted from 4 to 14 days and long treatment from 7 to 42 days but was at least 2 days longer than the corresponding short-course. At the end of treatment, we did not find any significant differences in clinical success [risk ratio (RR) 1.01; 95% confidence interval (CI), 0.96-1.07, moderate quality evidence] as well as in microbiological success (RR 0.99; 95% CI, 0.92-1.07, very low-quality evidence). At 4-6 weeks after the end of treatment there were no significant differences in clinical relapses (RR 1.20, 95% CI 0.43-3.30, very low-quality evidence) and re-infection of other germs (RR 2.40; 95% CI, 0.68-8.49, very low-quality evidence), even if short-term therapy seemed to have more risk of recurrences (RR 2.39, 95% CI 1.19-4.83, very low quality of evidence). The incidence of any adverse effect seemed to be lower with the short-term therapy, though the results are not statistically significant (RR 0.63, 95% CI 0.39-1.02, low quality evidence). Short-term treatment for aPN seems to be equivalent to long-term treatment in terms of clinical and microbiological success at the end of treatment or tolerability. The only relevant difference is the frequency of recurrence of the same biological germ up to 4-6 weeks after the end of treatment, which is significantly higher with the short-term therapy.

scholarly journals The Efficacy of Oral Terbinafine in the Short-term Treatment of Tinea Pedis

1995 ◽  
Vol 3 (1) ◽  
pp. 58
Author(s):  
Byoung Kook Kim ◽  
Jin Ho Chung ◽  
Jeong Aee Kim ◽  
Sang Eun Moon ◽  
Jai Il Youn
Keyword(s):  
Tinea Pedis ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Oral Terbinafine

Short-Term Therapy for Somatization Disorder: A Cognitive Behavioral Approach

2000 ◽  
Vol 14 (4) ◽  
pp. 373-380 ◽  
Author(s):  
Lesley A. Allen
Keyword(s):  
Term Treatment ◽  
Behavioral Approach ◽  
Cognitive Behavioral ◽  
Treatment Manual ◽  
Somatization Disorder ◽  
Term Therapy ◽  
Short Term ◽  
Short Term Treatment ◽  
Present Case Report

Somatization disorder is a distressing, disabling, and costly disorder. A short-term treatment manual, applying cognitive behavioral techniques to the maladaptive behaviors and thoughts associated with somatization disorder, was developed. The present case report examines the effectiveness of this 10-session treatment with a 38-year-old woman diagnosed with somatization disorder. The results show an improvement in the patient’s physical and emotional distress at termination, 6-month follow-up, and 12-month follow-up assessments.

Efficacy of ajoene, an organosulphur derived from garlic, in the short-term therapy of tinea pedis

Mycoses ◽  
1996 ◽  
Vol 39 (9-10) ◽  
pp. 393-395 ◽  
Author(s):  
E. Ledezma ◽  
L. De Sousa ◽  
A. Jorquera ◽  
J. Sanchez ◽  
A. Lander ◽  
...  
Keyword(s):  
Tinea Pedis ◽  
Term Therapy ◽  
Short Term ◽  
Short Term Therapy

scholarly journals Changes in three tumor markers in patients with advanced lung adenocarcinoma after combination therapy with pemetrexed and platinum: Short-term treatment efficacy

2021 ◽  
Vol 18 (3) ◽  
pp. 619-623
Author(s):  
Yang Lou ◽  
Bo Xu ◽  
Xianshuai Li ◽  
Xiaoyi Xu ◽  
Xianguo Chen
Keyword(s):  
Lung Adenocarcinoma ◽  
Tumor Markers ◽  
Tumor Volume ◽  
Term Treatment ◽  
Term Therapy ◽  
Research Subjects ◽  
Short Term ◽  
Short Term Treatment ◽  
Before And After ◽  
Volume Group

Purpose: To study changes in three tumor markers before and after combination treatment with pemetrexed and platinum, and evaluate the short-term therapeutic effectiveness of the treatment in advanced lung adenocarcinoma (ALA) subjects. Method: Patients with ALA (n =120) admitted to JinHua Municipal Central Hospital from January 2017 to May 2018 were selected as the research subjects. According to the results of chemotherapy, they were divided into two groups: significantly-reduced tumor volume group (90 cases), and nonsignificantly-reduced tumor volume group (21 cases). The two groups were treated with chemotherapy using a combination of pemetrexed and cisplatin. The levels of CEA, CA125 and CYFRA21-1 before and after chemotherapy were assayed to determine their relationship with short-term therapy effectiveness. Result: Overall analysis of tumor markers in the 120 patients with ALA showed statistically significant reduction in overall tumor marker levels before and after chemotherapy (p < 0.05). At the end of chemotherapy, the tumor markers were markedly reduced in subjects with significant tumor volume, and there was statistical difference between the two groups before chemotherapy (p < 0.05). Changes in CEA, CA125 and CYFRA21-1 were positively correlated with the chemotherapeutic effects on patients with ALA. Conclusion: In ALA patients treated with pemetrexed and platinum, changes in serum CEA, CA125 and CYFRA21-1 profiles before and after treatment depend on the effect of chemotherapy, and they are reliable for prediction of short-term therapeutic efficacy.

scholarly journals Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives

2021 ◽  
Vol 98 (12) ◽  
pp. 57-66
Author(s):  
A. E. Russkikh ◽  
D. M. Kutuzova ◽  
O. V. Lovacheva ◽  
A. G. Samoylova ◽  
I. A. Vasilyeva
Keyword(s):  
Multiple Drug Resistance ◽  
Term Treatment ◽  
Multiple Drug ◽  
Short Term ◽  
Short Term Treatment ◽  
Tuberculosis Patients ◽  
Treatment Regimens ◽  
Resistant Tuberculosis ◽  
Short Course ◽  
Multiple Drug Resistant

The article presents a review of 70 publications. It describes relevant data on drugs, timing, indications, efficacy, and safety of short-term treatment regimens for multiple drug resistant tuberculosis.

scholarly journals Short-term treatment with mycophenolic acid and tacrolimus is tolerogenic for INS-1 cell clone transplantation and the deleterious effects of the drugs are limited: in vivo and in vitro studies

2005 ◽  
Vol 186 (1) ◽  
pp. 213-220
Author(s):  
M Asfari ◽  
S Berta ◽  
S Coffy ◽  
M Kergoat ◽  
C Charon ◽  
...  
Keyword(s):  
Mycophenolic Acid ◽  
Cell Clone ◽  
Day Treatment ◽  
Immunosuppressive Drugs ◽  
Term Treatment ◽  
Β Cell ◽  
Short Term ◽  
Short Term Treatment

One of the major requirements for a successful and life-lasting organ transplant is the access to safe, least toxic and permanent tolerance-inducing drugs. In this study we wished to evaluate the effects of tolerogenic doses of the immunosuppressive drugs mycophenolic acid (MPA) and tacrolimus (Tac) on clonal β-cell lines, both in vivo and in vitro. Here we demonstrate that combined administration of low-dose MPA and Tac for 23 days induced permanent tolerance in an allogeneic β-cell line transplant in Wistar rat liver through the portal vein. This short-term treatment of tolerogenic doses of the two drugs was deleterious to the survival of the transplanted cells but a small percentage of the cells could resist the effect and become fully active when the drugs were removed. The surviving cells, retrieved from growth in vivo, did not exhibit increased resistance in comparison to the original cells when tested in vitro at two glucose concentrations, 10 and 20 mM. The presence of a small percentage of resistant cells at the two glucose concentrations was also detected in the in vitro study after a continuous 8-day treatment demonstrating that the in vivo resistance was not related to micro-environmental protection but possibly to a phenotypic cell state that is yet to be determined.

Effect of Enoxaparin on Homocysteine Concentration in Warfarin-Treated Patients

2002 ◽  
Vol 36 (9) ◽  
pp. 1355-1359 ◽  
Author(s):  
Yael Haviv ◽  
Aaron Lubetsky ◽  
Ben-Ami Sela ◽  
David Ezra ◽  
David Olchovsky
Keyword(s):  
Medical Center ◽  
Tertiary Care ◽  
Plasma Concentrations ◽  
Term Treatment ◽  
Term Therapy ◽  
Weekly Dose ◽  
Short Term ◽  
Short Term Treatment ◽  
Homocysteine Concentration ◽  
Plasma Thcy

BACKGROUND: Elevated plasma total homocysteine (tHcy) concentration is an emerging independent risk factor for hypercoagulability states and cardiovascular diseases. Many disease states and various drug treatment regimens are known to affect plasma tHcy concentration. OBJECTIVE: To examine the effect of short-term treatment with the low-molecular-weight heparin enoxaparin on plasma tHcy concentrations. METHODS: A prospective study was conducted in an outpatient anticoagulation clinic set in a tertiary care referral medical center. Subjects included twenty-four consecutive patients treated with warfarin who were scheduled for short-term enoxaparin treatment. Fasting plasma tHcy concentrations were measured before and after 3 days of enoxaparin treatment in patients who began short-term therapy with enoxaparin because of temporary inadequate anticoagulation (international normalized ratio <1.5). The main outcome measures were the difference in tHcy concentration between baseline and after enoxaparin treatment. RESULTS: tHcy plasma concentrations decreased in most patients (n = 21), did not change in 2, and increased in 1 patient after 3 days of enoxaparin treatment. The decline of tHcy was statistically significant: from 9.8 ± 3.4 to 7.6 ± 2.6 μmol/L (mean ± SD; p < 0.005). This decline was more prominent in patients with baseline tHcy plasma concentrations above the normal range compared with patients with normal baseline concentrations. Six patients in whom a third sample was obtained 15–30 days after the last enoxaparin injection developed decreased mean tHcy plasma concentrations: from 9.1 ± 3.0 μmol/L at baseline to 6.4 ± 2.0 μmol/L on day 3 and further to 5.7 ± 1.8 μmol/L on days 15–30. No relation was found between age, gender, treatment indication, and average weekly dose of warfarin to the presence or magnitude of tHcy plasma concentration decline. CONCLUSIONS: Short-term treatment with enoxaparin reduces plasma tHcy concentrations. Further studies are needed to clarify the mechanism and the clinical significance of enoxaparin's effect.

Sign in / Sign up

Export Citation Format

Share Document